Schrodinger
General Information | |
Business: |
Our differentiated, physics-based software platform enables discovery of high-quality, novel molecules for drug development and materials applications more rapidly, at lower cost, and with, we believe, a higher likelihood of success compared to traditional methods. Our software is used by biopharmaceutical and industrial companies, academic institutions, and government laboratories around the world, and we are the leading provider of computational software solutions for drug discovery. We also apply our computational platform to a broad pipeline of drug discovery programs in collaboration with biopharmaceutical companies, some of which we co-founded. In addition, we are using our platform to advance a pipeline of internal, wholly-owned drug discovery programs. |
Industry: | PHARMACEUTICAL PREPARATIONS |
Employees: | 392 |
Founded: | 1990 |
Contact Information | |
Address | 120 West 45th Street, 17th Floor, New York, NY 10036, US |
Phone Number | (212) 295-5800 |
Web Address | http://www.schrodinger.com |
View Prospectus: | Schrodinger |
Financial Information | |
Market Cap | $1044.6mil |
Revenues | $77.2 mil (last 12 months) |
Net Income | $-24.2 mil (last 12 months) |
IPO Profile | |
Symbol | SDGR |
Exchange | NASDAQ |
Shares (millions): | 11.9 |
Price range | $17.00 - $17.00 |
Est. $ Volume | $202.0 mil |
Manager / Joint Managers | Morgan Stanley/ BofA Securities/ Jefferies/ BMO Capital Markets |
CO-Managers | - |
Expected To Trade: | 2/6/2020 |
Status: | Priced |
Quiet Period Expiration Date: | Available only to Subscribers |
Lock-Up Period Expiration Date: | Available only to Subscribers |
SCOOP Rating | Available only to Subscribers |
Rating Change | Available only to Subscribers |